SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Rule 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 5, 2019
Zymeworks Inc.
(Exact name of registrant as specified in its charter)
|
British Columbia, Canada
|
001-38068
|
47-2569713
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
V6H 3V9
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
(604) 678-1388
|
||
|
(Registrant’s telephone number, including area code)
|
||
|
Not Applicable
|
||
|
(Former name of former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
| ITEM 8.01 |
OTHER EVENTS
|
The following information is filed pursuant to Item 8.01, “Other Events.”
On March 5, 2019, Zymeworks Inc. (the
“Company”) announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.
| ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS
|
| (d) | Exhibits | ||
|
Exhibit No.
|
Description
|
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
| ZYMEWORKS INC. | |||||
|
(Registrant)
|
|||||
|
Date: March 5, 2019
|
By:
|
/s/ Neil Klompas | |||
|
Name:
|
Neil Klompas
|
||||
|
Title:
|
Chief Financial Officer
|
||||
Exhibit 99.1
Zymeworks to Present at Barclays 2019 Global Healthcare Conference
Vancouver, Canada (March
5, 2019) – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced
that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.
The Company’s presentation will be on March 12, 2018 at 9:00 a.m. ET.
Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company’s
suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in
a Phase 1 clinical trial. The Company’s second clinical candidate, ZW49, is a bispecific antibody-drug conjugate in a Phase 1 clinical trial and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™
cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas and its therapeutic platforms have been leveraged through multiple strategic partnerships with eight global biopharmaceutical
companies. For more information, visit www.zymeworks.com.
Contacts:
Investors:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
Media:
Angela Bitting
(925) 202-6211
a.bitting@comcast.net